ClinicalTrials.gg
CompletedNCT05380947Updated Nov 4, 2025Results posted

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

A Phase 1 interventional study of BI 1810631 - trial formulation 1 (TF1) and BI 1810631 - new formulation (NF) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, but is planned to be replaced by another formulation (principle) in future clinical trials and on the market. This trial intends to bridge pharmacokinetics (PK) between the two formulation principles. For this, relative bioavailability of TF1 and new formulation (NF) is assessed. Moreover the trial intends to inform on the effect of food and of the proton pump inhibitor rabeprazole on the PK of BI 1810631 after administration as NF in order to inform management of food and concomitant medications.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 45 years (inclusive)
  • (BMI) of 18.5 to 29.9 weight divided by height squared (kg/m2) (inclusive)
  • Signed and dated written in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including blood pressure (BP), pulse rate (PR) or (ECG)) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • further exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Treatment sequence 1: R - T1 - T2 - T3

    Treatments: R: TF1 fasted T1: NF fasted T2: NF fed T3: NF fasted + rabeprazole

    Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium

  • Experimental
    Treatment sequence 2: T1 - T3 - R - T2

    Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium

  • Experimental
    Treatment sequence 3: T2 - R - T3 - T1

    Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium

  • Experimental
    Treatment sequence 4: T3 - T2 - T1 - R

    Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) was reported. Unit of geometric coefficient of variation (gCV) is %.

    Time frame: Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.

  2. Maximum Measured Concentration of BI 1810631 in Plasma (Cmax)

    The maximum measured concentration of BI 1810631 in plasma (Cmax) was reported. Unit of geometric coefficient of variation (gCV) is %.

    Time frame: Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) was reported. Unit of geometric coefficient of variation (gCV) is %.

    Time frame: Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.

07

Results

Posted Nov 4, 2025

Participant flow

This study was to investigate the relative bioavailability of 2 different BI 1810631 oral formulations (trial formulation 1 \[TF1\], Reference \[R\] and new formulation \[NF\], Test 1 \[T1\]) under fasting conditions; BI 1810631 NF under fasting (T1) and fed (T2) conditions; BI 1810631 NF given alone (T1) and together with the proton pump inhibitor rabeprazole (T3) under fasting conditions.

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - R
Started3433
Completed3433
Not completed0000
Washout Period 1
Participant flow — Washout Period 1
MilestoneTreatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - R
Started3433
Completed2433
Not completed1000
Withdrew: Not attend visit1000
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - R
Started2433
Completed2433
Not completed0000
Washout Period 2
Participant flow — Washout Period 2
MilestoneTreatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - R
Started2433
Completed1433
Not completed1000
Withdrew: Adverse event1000
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - R
Started1433
Completed1433
Not completed0000
Washout Period 3
Participant flow — Washout Period 3
MilestoneTreatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - R
Started1433
Completed1232
Not completed0201
Withdrew: Adverse event0100
Withdrew: Not attend visit0101
Period 4
Participant flow — Period 4
MilestoneTreatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - R
Started1232
Completed1232
Not completed0000

Outcome measures

PrimaryArea Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) was reported. Unit of geometric coefficient of variation (gCV) is %.

Time frame:
Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.
Reported as:
Geometric mean · hour * nanomole / Liter (h*nmol/L)
Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour * nanomole / Liter (h*nmol/L)TF1 Fasted (R)NF Fasted (T1)NF Fed (T2)NF Fasted + Rabeprazole (T3)
Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)4240 ± 52.75680 ± 18.84060 ± 13.75410 ± 27.6
Statistical analysis
  • TF1 Fasted (R) vs NF Fasted (T1) · Adjusted geometric means ratio (t1/r): 135.2 · 90% CI 99.7 to 183.6Unit of adjusted geometric means ratio (T1/R) is %. Unit of 90% Confidence Interval is %. Intra-individual geometric coefficient of variation (gCV) = 39.7%
  • NF Fasted (T1) vs NF Fed (T2) · Adjusted geometric means ratio (t2/t1): 74.2 · 90% CI 67.6 to 81.6Unit of adjusted geometric means ratio (T2/T1) is %. Unit of 90% Confidence Interval is %. Intra-individual geometric coefficient of variation (gCV) = 9.8%
  • NF Fasted (T1) vs NF Fasted + Rabeprazole (T3) · Adjusted geometric means ratio (t3/t1): 97.1 · 90% CI 85.8 to 110.0Unit of adjusted geometric means ratio (T3/T1) is %. Unit of 90% Confidence Interval is %. Intra-individual geometric coefficient of variation (gCV) = 13.8%
PrimaryMaximum Measured Concentration of BI 1810631 in Plasma (Cmax)

The maximum measured concentration of BI 1810631 in plasma (Cmax) was reported. Unit of geometric coefficient of variation (gCV) is %.

Time frame:
Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.
Reported as:
Geometric mean · nanomole / Liter (nmol/L)
Maximum Measured Concentration of BI 1810631 in Plasma (Cmax)
nanomole / Liter (nmol/L)TF1 Fasted (R)NF Fasted (T1)NF Fed (T2)NF Fasted + Rabeprazole (T3)
Maximum Measured Concentration of BI 1810631 in Plasma (Cmax)291 ± 93.1399 ± 37.3208 ± 31.4327 ± 34.2
Statistical analysis
  • TF1 Fasted (R) vs NF Fasted (T1) · Adjusted geometric means ratio (t1/r): 139.3 · 90% CI 87.7 to 221.3Unit of adjusted geometric means ratio (T1/R) is %. Unit of 90% Confidence Interval is %. Intra-individual coefficient of variation (gCV) = 62.3%
  • NF Fasted (T1) vs NF Fed (T2) · Adjusted geometric means ratio (t2/t1): 53.5 · 90% CI 40.5 to 70.8Unit of adjusted geometric means ratio (T2/T1) is %. Unit of 90% Confidence Interval is %. Intra-individual coefficient of variation (gCV) = 31.0%
  • NF Fasted (T1) vs NF Fasted + Rabeprazole (T3) · Adjusted geometric means ratio (t3/t1): 87.0 · 90% CI 66.8 to 113.2Unit of adjusted geometric means ratio (T3/T1) is %. Unit of 90% Confidence Interval is %. Intra-individual coefficient of variation (gCV) = 30.5%
SecondaryArea Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) was reported. Unit of geometric coefficient of variation (gCV) is %.

Time frame:
Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.
Reported as:
Geometric mean · hour * nanomole / Liter (h * nmol/L)
Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour * nanomole / Liter (h * nmol/L)TF1 Fasted (R)NF Fasted (T1)NF Fed (T2)NF Fasted + Rabeprazole (T3)
Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)4550 ± 52.75980 ± 19.24310 ± 14.25660 ± 28.8
Statistical analysis
  • TF1 Fasted (R) vs NF Fasted (T1) · Adjusted geometric means ratio (t1/r): 129.1 · 90% CI 96.2 to 173.4Unit of adjusted geometric means ratio (T1/R) is %. Unit of 90% Confidence Interval is %. Intra-individual coefficient of variation (gCV) =36.6%
  • NF Fasted (T1) vs NF Fed (T2) · Adjusted geometric means ratio (t2/t1): 74.9 · 90% CI 68.6 to 81.7Unit of adjusted geometric means ratio (T2/T1) is %. Unit of 90% Confidence Interval is %. Intra-individual coefficient of variation (gCV) = 9.0%
  • NF Fasted (T1) vs NF Fasted + Rabeprazole (T3) · Adjusted geometric means ratio (t3/t1): 96.9 · 90% CI 85.3 to 110.2Unit of adjusted geometric means ratio (T3/T1) is %. Unit of 90% Confidence Interval is %. Intra-individual coefficient of variation (gCV) = 14.2%

Adverse events

Collected over For R, T1, T2, and NF fasted + Rabeprazole (Rab.): From drug administration (admin.) till end of 14-day residual effect period (REP), up to 14 days. For Rab.: From drug admin. till end of REP of Rab., up to 8 days. All-cause mortality: From the first drug administration till end of trial, up to a total of 64 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TF1 Fasted (R)0/12 (0%)0/12 (0%)4/12 (33.3%)
NF Fasted (T1)0/12 (0%)0/12 (0%)1/12 (8.3%)
NF Fed (T2)0/9 (0%)0/9 (0%)4/9 (44.4%)
Rabeprazole0/11 (0%)0/11 (0%)2/11 (18.2%)
NF Fasted + Rabeprazole (T3)0/11 (0%)0/11 (0%)4/11 (36.4%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTF1 Fasted (R)NF Fasted (T1)NF Fed (T2)RabeprazoleNF Fasted + Rabeprazole (T3)
COVID-19Infections and infestations2/121/120/90/110/11
HaemorrhoidsGastrointestinal disorders0/120/121/90/110/11
NauseaGastrointestinal disorders0/120/121/90/110/11
SunburnInjury, poisoning and procedural complications0/120/121/90/110/11
RashSkin and subcutaneous tissue disorders0/120/121/90/110/11
FuruncleInfections and infestations0/120/120/91/110/11
HordeolumInfections and infestations0/120/120/91/110/11
DiarrhoeaGastrointestinal disorders0/120/120/90/111/11
ArthralgiaMusculoskeletal and connective tissue disorders0/120/120/90/111/11
MyalgiaMusculoskeletal and connective tissue disorders0/120/120/90/111/11

Baseline characteristics

Treated set (TS): the TS included all subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)Treatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - RTotal
Mean37.7 ± 7.033.5 ± 3.134.7 ± 8.534.0 ± 7.234.8 ± 5.8
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - RTotal
Female00000
Male343313
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - RTotal
Hispanic or Latino00000
Not Hispanic or Latino343313
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: R - T1 - T2 - T3Treatment Sequence 2: T1 - T3 - R - T2Treatment Sequence 3: T2 - R - T3 - T1Treatment Sequence 4: T3 - T2 - T1 - RTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American01001
White333312
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https:// www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Sep 2022, 2 months.

Results were first posted in Nov 2025, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2022
First posted
May 19, 2022
StartActual
Jun 23, 2022
Primary completionActual
Sep 13, 2022
CompletionActual
Sep 13, 2022
Results first posted
Nov 4, 2025
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05380947
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Jun 23, 2022
Primary completion
Sep 13, 2022
Completion
Sep 13, 2022
Results posted
Nov 4, 2025
Last update
Nov 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion